financetom
Business
financetom
/
Business
/
UiPath Unusual Options Activity For May 31
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UiPath Unusual Options Activity For May 31
May 31, 2024 8:37 AM

Investors with a lot of money to spend have taken a bullish stance on UiPath ( PATH ) .

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PATH, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 13 uncommon options trades for UiPath ( PATH ).

This isn't normal.

The overall sentiment of these big-money traders is split between 69% bullish and 30%, bearish.

Out of all of the special options we uncovered, 9 are puts, for a total amount of $627,814, and 4 are calls, for a total amount of $212,232.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $11.0 and $20.0 for UiPath ( PATH ), spanning the last three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for UiPath ( PATH ) options trades today is 1675.64 with a total volume of 4,797.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for UiPath's ( PATH ) big money trades within a strike price range of $11.0 to $20.0 over the last 30 days.

UiPath Option Volume And Open Interest Over Last 30 Days

Largest Options Trades Observed:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
PATH PUT TRADE BULLISH 01/17/25 $2.16 $2.08 $2.08 $12.50 $208.0K 5.2K 92
PATH CALL SWEEP BULLISH 07/19/24 $0.99 $0.96 $0.99 $12.00 $98.8K 1.1K 783
PATH PUT SWEEP BULLISH 01/16/26 $3.1 $2.94 $2.95 $12.50 $84.6K 3.9K 292
PATH PUT SWEEP BULLISH 01/16/26 $3.1 $2.94 $2.94 $12.50 $78.2K 3.9K 738
PATH PUT TRADE BULLISH 05/31/24 $2.98 $2.97 $2.97 $15.00 $53.7K 846 5

About UiPath

UiPath Inc ( PATH ) creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, the right to access certain software products it hosts (i.e., SaaS) and professional services. It generates a majority of its revenues from the Americas followed by Europe, Middle East, and Africa and Asia-Pacific.

Following our analysis of the options activities associated with UiPath ( PATH ), we pivot to a closer look at the company's own performance.

Present Market Standing of UiPath

With a volume of 12,892,967, the price of PATH is up 0.12% at $12.09.

RSI indicators hint that the underlying stock may be oversold.

Next earnings are expected to be released in 96 days.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UiPath ( PATH ) with Benzinga Pro for real-time alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
May 20, 2024
03:42 PM EDT, 05/20/2024 (MT Newswires) -- Travis Boersma, 10% Owner, Director, Executive Chairman of Board, on May 16, 2024, sold 439,510 shares in Dutch Bros ( BROS ) for $16,235,448. Following the Form 4 filing with the SEC, Boersma has control over a total of 1,039,239 shares of the company, with 1,039,239 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1866581/000186658124000170/xslF345X03/wk-form4_1716233953.xml Price: 36.64,...
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
May 20, 2024
03:49 PM EDT, 05/20/2024 (MT Newswires) -- Rio Tinto (RIO) has declared force majeure on alumina shipments from its Queensland, Australia refineries due to gas shortages, Bloomberg reported Monday, citing people familiar with the situation. The company notified clients of the decision on Monday, the people told Bloomberg. The shortage has affected the mining company's Yarwun refinery and Queensland Alumina,...
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
May 20, 2024
03:33 PM EDT, 05/20/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Monday the phase 3 trial of its lung disease treatment Dupixent as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease, or COPD, met primary endpoint. The trial showed a 34% reduction in moderate or severe COPD exacerbations over...
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
May 20, 2024
03:51 PM EDT, 05/20/2024 (MT Newswires) -- The independent lab that raised concerns about GSK's (GSK) Zantac heartburn medication has filed a whistleblower lawsuit against the UK drugmaker, alleging the company hid the drug's cancer risks for decades. The suit, filed in the US District Court for the Eastern District of Pennsylvania, by Valisure alleges GSK concealed data from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved